Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials

Comments
Loading...

Sign up for this week’s All Access giveaway here

Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma CANF, was a guest on Benzinga’s All Access on Nov 4, 2022.

Can-Fite is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The Company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development which address inflammatory, liver and metabolic diseases.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

CANF Logo
CANFCan Fite Biofarma Ltd
$1.40-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum16.76
Growth-
Quality-
Value47.55
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: